Psychedelic-Assisted Therapy (PAT) is emerging as a promising new treatment approach, with early success rates of 50–60% for conditions including treatment-resistant depression, severe post-traumatic stress disorder, anorexia, and substance use disorders. Recent polls suggest 13% of Americans felt depressed in the 2 weeks prior to being surveyed, while 46% of EU citizens felt depressed or anxious in the last 12 months, yet few new treatments have emerged for these pervasive mental health challenges.
How PAT Works
The Cambridge Psychedelic Research Group is leading clinical research into PAT, conducting trials with compounds including MDMA and psilocybin. The therapy operates across three phases: a preparation phase with a trained therapist lasting a few hours, where patients discuss their history and symptoms and receive coping tools; a dosing session supervised under drug effects lasting 6 to 8 hours, conducted in a carefully designed clinical setting with therapist support; and an integration session the day after dosing, where patients process and consolidate their experience.
Mechanisms of Action
Empathogens like MDMA promote empathy and compassion, allowing patients to revisit past traumas without overwhelming fear and anxiety. Neuroplastogens—including LSD, 5-MeO-DMT, and psilocybin—promote neuroplasticity and flexible cognition, helping patients escape rigid negative thought patterns. Early evidence shows neuroplastogens affect the body’s inflammatory response for weeks after treatment, potentially enhancing growth of new brain cell connections. Early results suggest around 60% of PTSD sufferers no longer meet PTSD criteria after treatment, with all trials reporting treatments were well tolerated with no substance misuse reported afterward.
Path to Integration
The CPRG is building evidence to integrate PAT into public health systems, with trials of group therapy scheduled for 2026. Researchers emphasize that PAT represents an intense, shorter intervention targeting root problems rather than just symptoms, potentially allowing full recovery rather than long-term symptom management alone.
This article is an AI-assisted summary. All facts and figures are drawn from the original report: https://www.cam.ac.uk/stories/your-guide-to-psychedelic-assisted-therapy